Abstract
Background & Aims: Terlipressin is crucial for treating acute oesophageal variceal bleeding (AEVB) and hepatorenal syndrome (HRS). This meta‐analysis compared the continuous versus bolus terlipressin infusion for treating the above conditions in patients with cirrhosis. Methods: Three major databases were searched for randomised controlled trials (RCTs) comparing two infusion strategies. A meta‐analysis was conducted to estimate the risk ratios (RR) with a 95% confidence interval (CI) based on a random‐effects model. Subgroup analyses were performed to account for adverse events (AEs) in terms of severity and organ systems. Additionally, a dose–response analysis was conducted to evaluate the correlation between drug dosage and AEs. Result: Six RCTs (494 patients) were included. Compared with bolus infusion, continuous terlipressin infusion showed less treatment failure (RR, 0.32; 95% CI, 0.12–0.87; p = 0.03), less rebleeding (RR, 0.52; 95% CI, 0.33–0.81; p < 0.01) and a trend toward lower mortality (RR, 0.62; 95% CI, 0.30–1.28; p = 0.19) in patients with AEVB, while response rates were comparable in patients with HRS (RR, 1.11; 95% CI, 0.87–1.41; p = 0.40) and a risk reduction of total AEs (RR, 0.59; 95% CI, 0.45–0.76; p < 0.01). Subgroup analyses stratifying AEs supported these findings, and a correlation was noted between drug dose and cardiovascular AEs. Conclusion: Compared to bolus administration, continuous terlipressin infusion reduces treatment failure and rebleeding rates in patients with AEVB; provides a comparable response rate in patients with HRS; and decreases the incidence of total, severe, and cardiovascular AEs while allowing for lower overall doses.

This publication has 24 references indexed in Scilit: